Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated March 30, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing specifically details transactions executed under a programme initiated on February 4, 2026.
Key Financial Metrics
The filing focuses on capital allocation activities rather than operational financial performance. Key metrics include:
- Total Repurchase Programme Cap: Up to DKK 15 billion over a 12-month period starting February 4, 2026.
- Specific Sub-Programme (Feb 4 - May 4, 2026): Up to DKK 3.8 billion.
- Shares Repurchased (as of March 27, 2026): 9,162,992 B shares.
- Total Transaction Value (as of March 27, 2026): DKK 2,399,878,368.
- Average Purchase Price: DKK 261.91 per B share.
- Treasury Shares Held: 26,552,791 B shares (0.6% of total share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the previous announcement on March 23, 2026, the company executed five additional transactions between March 23 and March 27, 2026. These transactions increased the accumulated number of repurchased shares from 7,847,992 to 9,162,992 and the total transaction value from DKK 2,091,696,255 to DKK 2,399,878,368.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total programme limit of DKK 15 billion during the 12-month period beginning February 4, 2026. The current sub-programme is scheduled to run until May 4, 2026.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard execution of the repurchase programme under EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 15 billion total programme (approximately DKK 12.6 billion remaining as of March 27, 2026).
- Confirm the average purchase price trend relative to the market price of B shares on Nasdaq Copenhagen.
- Review the full transaction details published on novonordisk.com for granular daily pricing data.
- Monitor the impact of the 0.6% treasury share holding on earnings per share (EPS) calculations in future reports.